<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680357</article-id><article-id pub-id-type="doi">10.3390/vaccines12121405</article-id><article-id pub-id-type="publisher-id">vaccines-12-01405</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Identifying the Gaps in Human Papillomavirus (HPV) Vaccine Uptake: An Exploratory Factor Analysis of Adults in Tennessee</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cernasev</surname><given-names>Alina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01405" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01405" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Oyedeji</surname><given-names>Oluwafemifola</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-vaccines-12-01405" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3682-360X</contrib-id><name><surname>Springer</surname><given-names>Cary M.</given-names></name><xref rid="af3-vaccines-12-01405" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5715-9173</contrib-id><name><surname>Hagemann</surname><given-names>Tracy M.</given-names></name><xref rid="af1-vaccines-12-01405" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0060-4643</contrib-id><name><surname>Hohmeier</surname><given-names>Kenneth C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01405" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3555-7805</contrib-id><name><surname>Kintziger</surname><given-names>Kristina W.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-vaccines-12-01405" ref-type="aff">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Voglino</surname><given-names>Gianluca</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Moro</surname><given-names>Giuseppina Lo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Gualano</surname><given-names>Maria Rosaria</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>De Vita</surname><given-names>Erica</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01405"><label>1</label>Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, 301 S. Perimeter Park Dr., Suite 220, Nashville, TN 37211, USA; <email>thageman@uthsc.edu</email> (T.M.H.); <email>khohmeie@uthsc.edu</email> (K.C.H.)</aff><aff id="af2-vaccines-12-01405"><label>2</label>Internal Medicine Residency Program, North Knoxville Medical Center, 7565 Dannaher Dr., Powell, TN 37849, USA; <email>oluwafemifola.oyedeji@tennova.com</email></aff><aff id="af3-vaccines-12-01405"><label>3</label>Research Computing Support, Office of Innovative Technologies, The University of Tennessee, 2309 Kingston Pike, Suite 132, Knoxville, TN 37996, USA; <email>springer@utk.edu</email></aff><aff id="af4-vaccines-12-01405"><label>4</label>Department of Environmental, Agricultural &#x00026; Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198, USA; <email>kkintziger@unmc.edu</email></aff><author-notes><corresp id="c1-vaccines-12-01405"><label>*</label>Correspondence: <email>acernase@uthsc.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1405</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>03</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>06</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Human papillomavirus (HPV) remains the most prevalent sexually transmitted infection in the United States (U.S.). By the age of 45, over 80% of Americans will contract HPV, which creates a significant public health concern. Despite the availability of effective vaccines, low vaccination uptake continues to be a challenge, particularly in Tennessee. Additionally, the Advisory Committee on Immunization Practices (ACIP) recently expanded recommendations for HPV vaccine usage to include adults aged 27&#x02013;45, suggesting a population with the potential to experience a gap in preventative care. To understand the underlying factors that may hinder Tennesseans from receiving the HPV vaccine, we conducted a cross-sectional survey from 29 June to 17 August 2023 among adults aged 18 to 45 in Tennessee. The survey was developed and informed by a scoping review regarding the various constructs and frameworks used in vaccine hesitancy and our previous qualitative work. Using theory-based instruments and previous qualitative data, this study aimed to determine the underlying factors that may hinder Tennesseans from receiving the HPV vaccine, focusing on those adults within the recently approved age range of 27&#x02013;45 years old. <bold>Methods:</bold> An Exploratory Factor Analysis of 2011 participants ultimately included five factors, which explain 70.3% of the variability. These were Benefits/Trust, Perceived Susceptibility, Attitude/Behavioral Control, Perceived Barriers, and Perceived Severity. All Cronbach alphas were greater than 0.80, indicating that each factor was reliable. <bold>Results:</bold> When stratifying by various demographics, our analysis found that race emerged as a significant factor (<italic toggle="yes">p</italic> = 0.002), while the interaction of race and vaccination status was not significant (<italic toggle="yes">p</italic> = 0.753). Black respondents had significantly lower levels of Benefits/Trust than White (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.030), with no significant differences between White and Asian respondents. <bold>Conclusions:</bold> These findings underscore the importance of researchers, healthcare professionals, public health officials, and policymakers in addressing these demographic differences to effectively increase vaccination rates and reduce HPV-associated cancer risks in Tennessee. Further studies are needed for targeted interventions to address these disparities.</p></abstract><kwd-group><kwd>HPV</kwd><kwd>HPV vaccine</kwd><kwd>survey</kwd><kwd>adults</kwd><kwd>U.S.</kwd></kwd-group><funding-group><award-group><funding-source>Investigator Initiated Studies Program of Merck Sharp &#x00026; Dohme LLC</funding-source></award-group><award-group><funding-source>Merck Sharp &#x00026; Dohme Corp</funding-source><award-id>A21-0065-001</award-id></award-group><funding-statement>This research is supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp &#x00026; Dohme LLC. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp &#x00026; Dohme LLC. This research received external funding from Merck Sharp &#x00026; Dohme Corp, under grant number A21-0065-001.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01405"><title>1. Introduction</title><p>Human papillomavirus (HPV) continues to be the most prevalent sexually transmitted infection in the United States (U.S.). Current reports from the Center for Disease Control and Prevention (CDC) suggest that the lifetime risk of infection is greater than 80% for women and 90% for men, with more than 80% of all Americans acquiring HPV by age 45 [<xref rid="B1-vaccines-12-01405" ref-type="bibr">1</xref>]. While most HPV infections are asymptomatic and will clear the body on their own, the consequences of HPV infection can be life-threatening. These negative outcomes include over 45,000 annual HPV-related cancer diagnoses in the U.S., including cervical, oropharyngeal, vulvar, vaginal, penile, and anal cancer, in addition to anogenital warts [<xref rid="B1-vaccines-12-01405" ref-type="bibr">1</xref>]. These outcomes pose a substantial financial burden of approximately USD 775 million in direct medical costs on the U.S. healthcare system [<xref rid="B2-vaccines-12-01405" ref-type="bibr">2</xref>].</p><p>HPV, a chronic sexually transmitted infection, is known to significantly impact the quality of life of affected patients, as evidenced by numerous studies [<xref rid="B3-vaccines-12-01405" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01405" ref-type="bibr">4</xref>]. For example, a study conducted in Iran reported changes in sexual function and quality of life (QoL) in women with HPV [<xref rid="B5-vaccines-12-01405" ref-type="bibr">5</xref>]. This study, while informative, also underscores the need for further research to fully understand the impact of sexual dysfunction associated with impaired sexual QoL [<xref rid="B5-vaccines-12-01405" ref-type="bibr">5</xref>].</p><p>To combat the spread of HPV and reduce morbidity and mortality, an effective strategy is proper utilization of the HPV vaccine. The first FDA approval of the HPV vaccine was for females in 2006, and approval for males followed soon after in 2011 [<xref rid="B6-vaccines-12-01405" ref-type="bibr">6</xref>]. Despite being included in the Healthy People 2020 and 2030 objectives, coverage and completion rates of the HPV vaccine have been historically low [<xref rid="B7-vaccines-12-01405" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01405" ref-type="bibr">8</xref>]. The suboptimal HPV vaccination coverage is more alarming in Tennessee. In 2020, the CDC reported that 1089 cancers were attributed to HPV in Tennessee [<xref rid="B9-vaccines-12-01405" ref-type="bibr">9</xref>]. Furthermore, a recent report from the Tennessee Immunization Information System showed that only 27.4% of adults aged 18 to 26 years in Tennessee were up to date with the vaccination series in 2023 [<xref rid="B10-vaccines-12-01405" ref-type="bibr">10</xref>].</p><p>The current guidelines from the Advisory Committee on Immunization Practices (ACIP) recommend catch-up HPV vaccination through the age of 26 for those who did not previously complete the series [<xref rid="B11-vaccines-12-01405" ref-type="bibr">11</xref>]. Furthermore, adults aged 27&#x02013;45 years who are not adequately vaccinated against HPV may receive the HPV vaccine series based on shared clinical decision-making [<xref rid="B11-vaccines-12-01405" ref-type="bibr">11</xref>]. Despite the current ACIP recommendations, vaccination rates remain suboptimal in adults aged 27&#x02013;45 years. Several studies have examined factors related to HPV vaccination in the adult population, which revealed barriers to vaccination such as healthcare accessibility, education level, race, and sex [<xref rid="B12-vaccines-12-01405" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-12-01405" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-01405" ref-type="bibr">14</xref>].</p><p>For example, people with an established healthcare provider are more likely to receive the HPV vaccine than those who do not have an established healthcare provider [<xref rid="B15-vaccines-12-01405" ref-type="bibr">15</xref>]. Another barrier to HPV vaccination is the level of education that one possesses. Those with a higher level of education are more likely to receive the vaccine. Additionally, although minority populations are disproportionately at a higher risk of morbidity and mortality attributed to HPV-related cancers, African American or Hispanic populations continue to have lower vaccination rates [<xref rid="B12-vaccines-12-01405" ref-type="bibr">12</xref>].</p><p>This study is the second part of a mixed-methods approach to understanding the perceptions, barriers, and facilitators of adults to receiving HPV and other recommended vaccines across diverse populations in Tennessee. The results from our qualitative components of this study have previously been published [<xref rid="B16-vaccines-12-01405" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01405" ref-type="bibr">17</xref>]. We used information obtained from a scoping review to develop a quantitative survey for adults between 18 and 45 years of age in Tennessee [<xref rid="B18-vaccines-12-01405" ref-type="bibr">18</xref>]. The objective of this survey was to determine the underlying factors that may hinder Tennesseans from receiving the HPV vaccine, focusing on those adults within the recently approved age range of 27&#x02013;45 years old.</p></sec><sec sec-type="methods" id="sec2-vaccines-12-01405"><title>2. Methods</title><sec id="sec2dot1-vaccines-12-01405"><title>2.1. Study Design and Population of Interest</title><p>We have previously described detailed study methods, including participant recruitment and survey development and administration [<xref rid="B16-vaccines-12-01405" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01405" ref-type="bibr">17</xref>]. Briefly, from 29 June to 17 August 2023, we conducted a cross-sectional study that included an online self-administered survey to understand the barriers and facilitators of HPV vaccination. Our population of interest included Tennessee residents aged 18 to 45 years, with a specific focus on patients from 27 to 45 years old.</p><p>We developed the survey after an extensive review of the literature, extracting relevant survey items from published studies examining HPV vaccination across a variety of populations and using a variety of health behavior theories [<xref rid="B18-vaccines-12-01405" ref-type="bibr">18</xref>]. Survey development was further informed by previous qualitative work that used focus groups to understand barriers and facilitators to HPV vaccination among adults in Tennessee [<xref rid="B16-vaccines-12-01405" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01405" ref-type="bibr">17</xref>]. Our investigative team, which included experts in infectious diseases, epidemiology, pharmaceutical sciences, internal medicine, and health promotion and behavior, reviewed the entire set of questions. Additionally, results from validity and reliability testing for each question allowed researchers to make recommendations, including changes to wording, and missing items. A final set of proposed questions was sent to external reviewers, including experts in similar fields as our investigative team, for feedback. After incorporating this feedback, 31 survey items made up our final list of questions covering a variety of theoretical constructs across Theory of Planned Behavior, Social Cognitive Theory, and Health Belief Model, as well as investigator-developed items.</p><p>For survey questions relative to this analysis, we used 7-point Likert scales for responses to determine theoretical constructs that were positively and negatively associated with HPV vaccine measures. Possible responses ranged from &#x0201c;completely disagree&#x0201d; to &#x0201c;completely agree&#x0201d;. The questions included in this analysis were items representing specific theoretical constructs (i.e., Subjective Norms, Attitudes, Perceived Behavioral Control, Perceived Susceptibility, Perceived Severity, Perceived Barriers, Perceived Benefits, and Trust). We used a Qualtrics<sup>XM</sup> (Provo, UT, USA) panel to ensure that the study sample represented our population of interest in terms of age, gender, race, ethnicity, religion, and residence.</p></sec><sec id="sec2dot2-vaccines-12-01405"><title>2.2. Data Categorization</title><p>To ensure adequate representation of the sample, we incorporated questions related to age and ZIP code of residence to determine eligibility and other demographic characteristics. These variables included sex at birth, race, ethnicity, relationship status, education, and political and religious views. We recategorized the following variables based on data distribution, small sample sizes in certain categories, or needs for data analysis.</p><p>We stratified age as 18&#x02013;28, 29&#x02013;38, and 39&#x02013;45 years. These age groups are of paramount importance in the context of HPV vaccination. They encompass adults who are or were eligible for the HPV vaccine, incorporating the expanded ACIP recommendations [<xref rid="B11-vaccines-12-01405" ref-type="bibr">11</xref>]. This underscores the critical role these age groups play in the vaccination landscape. The geographic region of Tennessee residents was categorized based on ZIP codes using the ZIP code approximation of the 2010 Rural-Urban Commuting Area (RUCA) codes [<xref rid="B19-vaccines-12-01405" ref-type="bibr">19</xref>]. RUCA codes were categorized as urban, suburban, large rural, and small rural areas. This comprehensive approach significantly enhances our understanding of the perceived barriers to accessing the HPV vaccine. Race/ethnicity was defined by self-selected survey categories: White, Black, Asian, and others (combined due to small cell sizes). For education level, the stratification was comprehensive, covering less than high school, high school graduate, some college, Associate/Bachelor degree, and Master/Doctoral/Professional degree. Study participants were asked questions about their sexual orientation, such as straight/heterosexual and other, and current relationship status, such as married/partnered/engaged and single/separated/divorced. Political leanings were defined by self-selected survey categories: liberal, moderate, and conservative. Study participants had the following options for employment: employed full or part-time, unemployed seeking/not seeking/disabled, and student.</p></sec><sec id="sec2dot3-vaccines-12-01405"><title>2.3. Statistical Methods</title><p>We used Exploratory Factor Analysis (EFA) with an orthogonal (Varimax with Kaiser Normalization) rotation to improve the interpretability of our extracted latent constructs that influence HPV-vaccine decisions and uptake. We excluded one question on intention and one question related to Perceived Severity as they were only asked in either the vaccinated or unvaccinated groups, rather than both. The initial Factor Analysis included 29 questions pertaining to the seven theoretical constructs that were asked in both the vaccinated and unvaccinated samples. Factor loadings, which measure the relationship (i.e., strength and direction) of the item (i.e., variable) to the extracted factor, are reported. The final Factor Analysis included 25 items and the identified underlying factors. Two sets of hypothesized factors ended up loading together. Items for Benefits and Trust loaded into a single factor and items for attitudes and behavior control loaded together. We choose to report these five factors based on examining scree plots, factor loadings greater than 1, and comparing results of other EFA considering more or fewer factors on loadings and conceptual clarity. Four questions were removed based on this analysis, including three questions related to subjective norms due to greater variability within responses and one question related to trust due to concerns over interpretation of wording.</p><p>Survey item responses were given a value based on the 7-point Likert scale (e.g., 1 being &#x0201c;completely disagree&#x0201d; and 7 being &#x0201c;completely agree&#x0201d; depending on the directionality of the question). Survey items were averaged to create a mean score for each factor. That is, individuals&#x02019; responses to the survey items included in each factor were averaged to give every respondent a factor score, and then these scores were averaged across all respondents to provide a mean score for each factor. These averaged factor scores were used in the relational and comparative statistical analyses. We analyzed relationships between the factors using Pearson&#x02019;s correlation coefficient (r).</p><p>Additionally, we used Multivariate Analysis of Variance (MANOVA) to determine differences in the five factors by demographic characteristics of interest. If the overall MANOVA tests were significant, indicating at least one of the factors differed by category of the demographic variable, we used individual Analysis of Variance (ANOVA) models with appropriate post hoc tests to determine which categories differed. Means and standard deviations (SD), overall MANOVA F-test <italic toggle="yes">p</italic>-value, and individual ANOVA F-test <italic toggle="yes">p</italic>-values were reported. We conducted all analyses in SPSS 29 (IBM Corp; Armonk, NY, USA) with a Type I error rate of 0.05.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01405"><title>3. Results</title><p>In this study, a total of 2011 participants provided complete surveys. The participants were more likely to be female (52.2%), White (81.2%), non-Hispanic (94.0%), aged 18&#x02013;28 years (49.8%), with a high school diploma (37.4%), be politically moderate (37.2%), employed (68.0%), straight/heterosexual (77.9%), and single (56.0%). The majority of participants had not received a HPV vaccination (57.3%).</p><sec id="sec3dot1-vaccines-12-01405"><title>3.1. Exploratory Factor Analysis</title><p>The final EFA included 25 items that loaded on five factors, which explain 70.3% of the variability in HPV vaccine-seeking behaviors in adults. These factors included the following:<list list-type="bullet"><list-item><p>Factor 1: Benefits/Trust;</p></list-item><list-item><p>Factor 2: Perceived Susceptibility;</p></list-item><list-item><p>Factor 3: Attitudes/Behavioral Control;</p></list-item><list-item><p>Factor 4: Perceived Barriers;</p></list-item><list-item><p>Factor 5: Perceived Severity.</p></list-item></list></p><p><xref rid="vaccines-12-01405-t001" ref-type="table">Table 1</xref> summarizes the survey items included in each factor and factor loadings. All factor loadings were 0.600 or higher, indicating strong correlations between the items and the factor. <xref rid="vaccines-12-01405-t002" ref-type="table">Table 2</xref> contains the mean and standard deviation (SD) of each factor and the proportion of variance explained, as well as a measure of each factor&#x02019;s internal reliability (Cronbach&#x02019;s alpha). Factors 1 (Benefits/Trust) and 5 (Perceived Severity) had mean scores over 5, indicating individuals agreed with these factors. Factor 2 (Perceived Susceptibility) had a mean under 4, indicating disagreement. Each factor explained over 10% of the variability in HPV vaccine-seeking behaviors, with factor 1 (Benefits/Trust) explaining almost 20%. All Cronbach alphas were greater than 0.80, indicating that each factor was reliable. All factors were positively correlated with the others, except for Factor 4 (Perceived Barriers), which had a significant negative correlation with Factor 3 (r = &#x02212;0.157, <italic toggle="yes">p</italic> &#x0003c; 0.001), a weak positive correlation with Factor 5 (r = 0.089, <italic toggle="yes">p</italic> &#x0003c; 0.001), and no significant correlation with the remaining factors (<xref rid="vaccines-12-01405-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot2-vaccines-12-01405"><title>3.2. Latent Factors by Demographic Characteristics</title><p><xref rid="vaccines-12-01405-t004" ref-type="table">Table 4</xref>, <xref rid="vaccines-12-01405-t005" ref-type="table">Table 5</xref>, <xref rid="vaccines-12-01405-t006" ref-type="table">Table 6</xref> and <xref rid="vaccines-12-01405-t007" ref-type="table">Table 7</xref> provide the results of the MANOVA and individual ANOVAs for significant associations with demographic characteristics of interest.</p><p><underline>Vaccination Status.</underline> All factors, except Factor 4 (Perceived Barriers), were found to be significantly higher (all <italic toggle="yes">p</italic>-values &#x0003c; 0.001) for those who were vaccinated, including Benefits/Trust, Perceived Susceptibility, Attitudes/Behavioral Control, and Perceived Severity. Notably, Factor 4 was significantly higher for those not vaccinated (<xref rid="vaccines-12-01405-t004" ref-type="table">Table 4</xref>).</p><p><underline>Age.</underline> The results of the MANOVA indicated that at least one factor had a significant age-by-vaccination status interaction (<italic toggle="yes">p</italic> = 0.004) and a significant main effect of age (<italic toggle="yes">p</italic> &#x0003c; 0.001). The individual ANOVAs played a crucial role in confirming the significance of age, revealing significant age-group differences for several factors (<xref rid="vaccines-12-01405-t005" ref-type="table">Table 5</xref>). For Factor 1 (Benefits/Trust), neither the main effect of age group (<italic toggle="yes">p</italic> = 0.112) nor the interaction of age group and vaccination status (<italic toggle="yes">p</italic> = 0.303) were significant.</p><p>Factor 2 (Perceived Susceptibility) had a significant age-by-vaccination status interaction (<italic toggle="yes">p</italic> = 0.002). To explore this interaction, age groups were compared within each vaccination status. Within the unvaccinated group, no age differences were identified (all <italic toggle="yes">p</italic>-values &#x0003e; 0.05). Within the vaccinated group, those aged 18&#x02013;28 years old had significantly lower Perceived Susceptibility than those aged 39&#x02013;45 years old (<italic toggle="yes">p</italic> = 0.007). No other significant differences were identified.</p><p>Factor 3 (Attitudes/Behavioral Control) revealed a significant main effect of age (<italic toggle="yes">p</italic> = 0.001), a finding of particular significance. The interaction of age group and vaccination status was not significant (<italic toggle="yes">p</italic> = 0.060). Pairwise comparisons were run to determine how age groups differed. Individuals aged 29&#x02013;38 years old had significantly higher Attitude/Behavioral Control than individuals aged 18&#x02013;28 years old (<italic toggle="yes">p</italic> = 0.036) and 39&#x02013;45 years old (<italic toggle="yes">p</italic> = 0.002). No difference was found between 18&#x02013;28- and 39&#x02013;45-year age groups (<italic toggle="yes">p</italic> = 0.156). In Factor 4, it is worth noting that neither the main effect of age (<italic toggle="yes">p</italic> = 0.167) nor the interaction of age and vaccination status (<italic toggle="yes">p</italic> = 0.213) were significant.</p><p>Factor 5 (Perceived Severity) revealed a significant main effect of age (<italic toggle="yes">p</italic> &#x0003c; 0.001), a finding that significantly impacts the interpretation of the results. The interaction of age and vaccination status was not significant (<italic toggle="yes">p</italic> = 0.080). Pairwise comparisons showed that individuals aged 18&#x02013;28 years old had significantly lower Perceived Severity than individuals 29&#x02013;38 years old (<italic toggle="yes">p</italic> = 0.011) and 39&#x02013;45 years old (<italic toggle="yes">p</italic> &#x0003c; 0.001). There was no difference between 28&#x02013;38 and 39&#x02013;45-year age groups (<italic toggle="yes">p</italic> = 0.362).</p><p><underline>Sex at Birth.</underline> The MANOVA results indicated a significant effect of sex (<italic toggle="yes">p</italic> &#x0003c; 0.001) with at least one factor. Sex by vaccination status was not substantial (<italic toggle="yes">p</italic> = 0.414). To determine how sex differs by factor, individual ANOVAs were examined. Significant sex differences were found with Factor 2 (<italic toggle="yes">p</italic> = 0.029) and Factor 4 (<italic toggle="yes">p</italic> &#x0003c; 0.001). Males had significantly higher levels of Perceived Susceptibility, but considerably lower levels of Perceived Severity than females (<xref rid="vaccines-12-01405-t006" ref-type="table">Table 6</xref>).</p><p><underline>Race.</underline> The analysis focused on three racial groups, White, Black, and Asian participants, due to limited sample sizes in other categories. The results of the MANOVA revealed a significant interaction between race and vaccination status (<italic toggle="yes">p</italic> = 0.026), as well as a significant main effect of race (<italic toggle="yes">p</italic> &#x0003c; 0.001) across at least one factor. Further examination through individual ANOVAs and post hoc analyses unveiled significant differences in perceptions related to vaccination across these racial groups (<xref rid="vaccines-12-01405-t007" ref-type="table">Table 7</xref>).</p><p>Factor 1 (Benefits/Trust) revealed significant findings. Race emerged as a significant factor (<italic toggle="yes">p</italic> = 0.002), while the interaction of race and vaccination status was not significant (<italic toggle="yes">p</italic> = 0.753). Black respondents had significantly lower levels of Benefits/Trust than White (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.030), with no significant differences between White and Asian respondents. For Factor 2 (Perceived Susceptibility), there was a significant race&#x02013;vaccination status interaction (<italic toggle="yes">p</italic> = 0.006). To explore this interaction, race was compared within each vaccination status. Within the vaccinated group, no race differences were identified (all <italic toggle="yes">p</italic>-values &#x0003e; 0.05). Within the unvaccinated group, White respondents had significantly lower Perceived Susceptibility than Black (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.009). No significant differences were noted between Black and Asian respondents.</p><p>Factor 3 (Attitudes/Behavioral Control) had both significant overall (<italic toggle="yes">p</italic> &#x0003c; 0.001) and interaction effects between race and vaccination status (<italic toggle="yes">p</italic> = 0.039). In the unvaccinated group, Asian respondents had significantly higher Attitudes/Behavioral Control than both White (<italic toggle="yes">p</italic> = 0.001) and Black respondents (<italic toggle="yes">p</italic> &#x0003c; 0.001), with no significant differences between Asian and Black respondents. In the vaccinated group, Black respondents scored significantly lower on Attitudes/Behavioral Control compared to White (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.035). For Factor 4 (Perceived Barriers), neither the main effect of race (<italic toggle="yes">p</italic> = 0.820) nor the interaction of race and vaccination status (<italic toggle="yes">p</italic> = 0.402) were significant. For Factor 5 (Perceived Severity), the main effect of race was significant (<italic toggle="yes">p</italic> &#x0003c; 0.001), while the interaction of race and vaccination status was not (<italic toggle="yes">p</italic> = 0.993). Pairwise comparisons showed that Black respondents had significantly lower Perceived Severity scores than White (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.039), with no differences between White and Asian respondents (<italic toggle="yes">p</italic> = 0.688).</p><p><underline>Location.</underline> No overall difference in factors was identified for location (<italic toggle="yes">p</italic> = 0.180), and the results are not reported.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01405"><title>4. Discussion</title><p>This study&#x02019;s aim was to determine the underlying factors that may be associated with of the rate of uptake of the HPV vaccine among Tennesseans, focusing on those adults within the most recently approved age range of 27&#x02013;45 years old. It further builds on previous work given that in our sample of 2011 online surveys, most patients were not vaccinated for HPV (57.3%), and were female, single, employed, straight/heterosexual, White, non-Hispanic, and between the ages of 18&#x02013;28 years [<xref rid="B20-vaccines-12-01405" ref-type="bibr">20</xref>].</p><p>Our study&#x02019;s findings demonstrated a significant increase (all <italic toggle="yes">p</italic>-values &#x0003c; 0.001) in Benefits/Trust, Perceived Susceptibility, Attitudes/Behavioral Control, and Perceived Severity among vaccinated people. It also underscores the potentially important role of healthcare providers in supporting and guiding patients through the vaccination process, making them an integral part of this decision. This could be useful information when designing future prospective studies or interventions to improve HPV vaccination rates in Tennessee or similar states. Additionally, this emphasizes the importance of improving education and communication around such a crucial topic. A study was conducted with minority women in the U.S. regarding the factors impacting the vaccination uptake in two age groups: 18&#x02013;26 and 27&#x02013;45 [<xref rid="B21-vaccines-12-01405" ref-type="bibr">21</xref>]. The findings revealed that the healthcare provider&#x02019;s recommendation was the most influential aspect of receiving the HPV vaccine [<xref rid="B21-vaccines-12-01405" ref-type="bibr">21</xref>]. The study also highlighted other factors, including conversations about the benefits of receiving the vaccine with a doctor, having health insurance, and disclosing of sexual orientation to the healthcare providers [<xref rid="B21-vaccines-12-01405" ref-type="bibr">21</xref>]. Healthcare providers can encourage conversations with those who feel they are not open to discussing the benefits of and concerns with vaccination. It is important to note that a strong recommendation from a healthcare provider has a significant impact on HPV vaccine intention and uptake, as shown in previous studies [<xref rid="B22-vaccines-12-01405" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01405" ref-type="bibr">23</xref>]. Despite the positive attitudes of the surveyed respondents in these studies, administration rates remained low, especially in the Southern U.S.</p><p>To enhance vaccination rates among eligible adults residing in the Southern U.S, it is imperative that targeted programs and policies are developed. Interventions that explore the influence of various healthcare professionals might be needed to address vaccine hesitancy and motivational barriers, such as the belief that the HPV vaccine is unnecessary or unsafe. These possible interventions include educational campaigns when adults visit other healthcare professionals, such as dental offices. Many oropharyngeal cancers are HPV in origin and are screened for by the dentist. One study surveyed dentists, hygienists, and dental students&#x02019; attitudes toward the HPV vaccine, focusing on their willingness to administer it in office [<xref rid="B24-vaccines-12-01405" ref-type="bibr">24</xref>]. Most respondents, particularly students, expressed willingness to administer the HPV vaccine if legally permitted [<xref rid="B24-vaccines-12-01405" ref-type="bibr">24</xref>]. The findings suggest a potential for broader professional scope with HPV vaccine administration in dental settings as a potential avenue to highlight additional strategies to enhance vaccine uptake rates. To address this, future studies may explore targeted interventions for adults who visit dental offices.</p><p>While the currently available HPV vaccines have demonstrated effectiveness in prevention of HPV infections, research has pointed toward possibilities of treating various HPV-related conditions (REF) [<xref rid="B25-vaccines-12-01405" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01405" ref-type="bibr">26</xref>]. This may lead to a greater use of these vaccines, and enhance the need for targeted educational campaigns and outreach by healthcare providers, especially in these populations [<xref rid="B27-vaccines-12-01405" ref-type="bibr">27</xref>].</p><p>Our survey respondents showed that race emerged as a significant factor (<italic toggle="yes">p</italic> = 0.002), while the interaction of race and vaccination status was not significant (<italic toggle="yes">p</italic> = 0.753). Our findings demonstrated that Black respondents had significantly lower levels of Benefits/Trust than White (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.030), with no significant differences between White and Asian respondents. Our findings also echo previous conclusions of the literature regarding the level of Benefits/Trust. Walter et al. in 2020 sampled women residing in the Southern U.S. aged 18&#x02013;32 who visited the emergency department [<xref rid="B28-vaccines-12-01405" ref-type="bibr">28</xref>]. The study reported that the White respondents were significantly more likely to be aware of the HPV vaccine compared to Black or African American respondents [<xref rid="B28-vaccines-12-01405" ref-type="bibr">28</xref>]. Regarding the vaccination rates in this sampled population, it was reported that White respondents are more likely to have received the HPV vaccine than Black or African American respondents [<xref rid="B28-vaccines-12-01405" ref-type="bibr">28</xref>]. These findings underscore the importance of our research in understanding and addressing disparities in vaccination awareness and uptake. Similarly, a recent study investigated the differences in awareness of the HPV vaccine among racial and ethnic minority groups in the U.S. [<xref rid="B29-vaccines-12-01405" ref-type="bibr">29</xref>]. The study used data from the 2018 Health Information National Trends Survey (HINTS) and found significant disparities in awareness levels [<xref rid="B29-vaccines-12-01405" ref-type="bibr">29</xref>]. According to the study, Asian Americans showed the lowest awareness of both HPV and the HPV vaccine compared to other racial and ethnic groups [<xref rid="B30-vaccines-12-01405" ref-type="bibr">30</xref>]. Future studies should use this evidence to inform the development of targeted interventions or adaptation of existing interventions to increase HPV vaccine intention and uptake in minority groups. This would ultimately reduce the burden of HPV-associated cancers.</p><p>Our study, which compares race with HPV vaccination status, has important implications. Within the vaccinated group, no race differences were identified (all <italic toggle="yes">p</italic>-values &#x0003e; 0.05). However, within the unvaccinated group, White respondents had significantly lower Perceived Susceptibility than Black (<italic toggle="yes">p</italic> &#x0003c; 0.001) and Asian respondents (<italic toggle="yes">p</italic> = 0.009). Previous research regarding race comparisons has shown that higher HPV knowledge scores were associated with vaccine series completion [<xref rid="B30-vaccines-12-01405" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01405" ref-type="bibr">31</xref>]. Those who perceived the vaccine as more beneficial were more likely to have completed the series [<xref rid="B30-vaccines-12-01405" ref-type="bibr">30</xref>]. Oh et al. (2021) reported that African American students were less likely to complete the series compared to non-Hispanic White students [<xref rid="B32-vaccines-12-01405" ref-type="bibr">32</xref>]. Further studies are needed for targeted interventions to address these disparities.</p></sec><sec id="sec5-vaccines-12-01405"><title>5. Limitations</title><p>We originally planned on conducting a secondary survey in this population, with the intent of performing confirmatory analyses. However, due to changes in university system contracts, the original survey&#x02019;s deployment was significantly delayed. Based on our preliminary results and significant findings, we decided to postpone additional surveys to ensure the timely publication of this work.</p><p>Furthermore, due to the above challenges, two aspects of the survey design were overlooked, which unfortunately had the potential to impact study findings. This limited our ability to include one question on Perceived Severity and led to the incorrect categorization of age groups (for example, 18&#x02013;28 and 29&#x02013;38 instead of 18&#x02013;26 and 27&#x02013;36). However, based on the resulting data, this did not appear to significantly alter our results.</p><p>These findings are from a convenience sample of Tennesseans and may not represent the entire population of the state and might not be applicable to other states. However, our study included a large sample of respondents across Tennessee and was designed to match the demographic characteristics of the state in terms of age, gender, race, ethnicity, religion, and residence. The results indicate that our sample successfully matched the demographic characteristics of Tennessee, compared to U.S. Census data. Further, even within this limited focus, knowledge about HPV varied based on age, education level, and attitudes toward vaccination. States with similar demographic, cultural, and religious beliefs as Tennessee may identify similar patterns in constructs among vaccinated individuals.</p><p>Finally, surveys that rely on self-reported responses are subject to risk of recall bias or social desirability bias. We asked questions about HPV vaccination amidst a list of other standard vaccinations to decrease social desirability bias and increase the likelihood of recall. The survey was also conducted online, further reducing the risk of inaccurate reporting due to social stigma. Our sample included participants between the ages of 18 and 45 years, with oversampling in the 18&#x02013;26-year range, so the sample is likely to have a more accurate recall of vaccination events that occurred recently. Further, we asked about vaccination history using targeted, structured questions that included prompts about offered versus received vaccines. We did not ask about dates of vaccination or number of doses. Our rate of vaccination in this sample (42.7%) is higher than the rate reported for Tennessee in 2022 (26.1% in 18&#x02013;26-year-old participants) [<xref rid="B33-vaccines-12-01405" ref-type="bibr">33</xref>]. The state HPV vaccination rate is likely to be an underrepresentation as data do not include information on those over 26 years of age, and it only includes mandatory reporting of federally funded vaccines. All other vaccine reporting is voluntary in Tennessee [<xref rid="B10-vaccines-12-01405" ref-type="bibr">10</xref>].</p></sec><sec id="sec6-vaccines-12-01405"><title>6. Strengths</title><p>To our knowledge, our study is the first to explore barriers and facilitators to HPV vaccination in Tennessee and one of the first to specifically study these factors related to HPV vaccination in adults aged 27 to 45 years since the revised ACIP recommendations. The survey development was informed by the scoping review regarding the various constructs and frameworks used in vaccine hesitancy and the qualitative work. By partnering with an external company experienced in survey deployment and capturing representative survey samples, we were able to ensure that we had an adequate sample size in our exploratory survey deployment that was representative of our target population.</p></sec><sec sec-type="conclusions" id="sec7-vaccines-12-01405"><title>7. Conclusions</title><p>Our study found important associations between certain constructs or key concepts such as Benefits/Trust, Perceived Susceptibility, Attitudes/Behavioral Control, and Perceived Severity among vaccinated people. Such information is useful for informing future prospective studies or interventions. Our results demonstrate that healthcare practitioners must be cognizant of the existence of factors that hinder HPV vaccine uptake in Tennesseans. Most significantly, providers should consider the impact of sex and race, as these demographics are where most underlying disparities in this population exist. Attention to these characteristics and anticipation of vaccine hesitancy will also establish provider trust, which further influences the decision for many adults to get vaccinated. Awareness of these details will be useful in addressing additional obstacles that may arise for adults between 18 and 45 years who are contemplating HPV vaccination.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.C., T.M.H., K.C.H. and K.W.K.; methodology, K.W.K. and C.M.S.; software, C.M.S.; validation, K.W.K. and C.M.S.; formal analysis, C.M.S.; investigation, A.C. and K.W.K.; resources, A.C., T.M.H., K.C.H., K.W.K. and O.O.; writing&#x02014;original draft preparation, A.C., T.M.H., K.C.H., O.O., C.M.S. and K.W.K.; writing&#x02014;review and editing, A.C., O.O., T.M.H., K.C.H., C.M.S. and K.W.K.; project administration, A.C., T.M.H. and K.W.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the University of Tennessee Health Science Center (IRB # 21-08416-XM, approved 3 November 2021).</p></notes><notes><title>Informed Consent Statement</title><p>Participant consent was received from all the participants prior to conducting the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01405"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention</collab>
</person-group><article-title>HPV and Oropharyngeal Cancer</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/cancer/hpv/oropharyngeal-cancer.html?CDC_AAref_Val=https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.htm" ext-link-type="uri">https://www.cdc.gov/cancer/hpv/oropharyngeal-cancer.html?CDC_AAref_Val=https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-12">(accessed on 12 March 2024)</date-in-citation></element-citation></ref><ref id="B2-vaccines-12-01405"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>S.W.</given-names></name>
<name><surname>Lattimore</surname><given-names>D.C.</given-names></name>
<name><surname>Harlin</surname><given-names>E.</given-names></name>
<name><surname>Davis</surname><given-names>L.</given-names></name>
<name><surname>Erholtz</surname><given-names>V.</given-names></name>
<name><surname>Brandt</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Medical and public health professionals&#x02019; perceived facilitators and barriers of human papillomavirus (HPV) vaccination among African American adolescents in Shelby County, Tennessee</article-title><source>BMC Health Serv. Res.</source><year>2023</year><volume>23</volume><elocation-id>469</elocation-id><pub-id pub-id-type="doi">10.1186/s12913-023-09415-6</pub-id><pub-id pub-id-type="pmid">37165427</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01405"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciccarese</surname><given-names>G.</given-names></name>
<name><surname>Drago</surname><given-names>F.</given-names></name>
<name><surname>Copello</surname><given-names>F.</given-names></name>
<name><surname>Bodini</surname><given-names>G.</given-names></name>
<name><surname>Rebora</surname><given-names>A.</given-names></name>
<name><surname>Parodi</surname><given-names>A.</given-names></name>
</person-group><article-title>Study on the impact of sexually transmitted infections on Quality of Life, mood and sexual function</article-title><source>Ital. J. Dermatol. Venereol.</source><year>2020</year><volume>156</volume><fpage>686</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.23736/S0392-0488.20.06796-6</pub-id></element-citation></ref><ref id="B4-vaccines-12-01405"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graziottin</surname><given-names>A.</given-names></name>
<name><surname>Serafini</surname><given-names>A.</given-names></name>
</person-group><article-title>HPV infection in women: Psychosexual impact of genital warts and intraepithelial lesions</article-title><source>J. Sex. Med.</source><year>2009</year><volume>6</volume><fpage>633</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2008.01151.x</pub-id><pub-id pub-id-type="pmid">19170869</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01405"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tehranian</surname><given-names>A.</given-names></name>
<name><surname>Dastjerdi</surname><given-names>M.V.</given-names></name>
<name><surname>Hatamian</surname><given-names>S.</given-names></name>
<name><surname>Ghahghaei-Nezamabadi</surname><given-names>A.</given-names></name>
</person-group><article-title>Sexual Function and Quality of Life in Iranian Women With Human Papillomavirus Infection</article-title><source>J. Fam. Reprod. Health</source><year>2024</year><volume>18</volume><fpage>154</fpage><pub-id pub-id-type="doi">10.18502/jfrh.v18i3.16656</pub-id></element-citation></ref><ref id="B6-vaccines-12-01405"><label>6.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Food and Drug Administration</collab>
</person-group><article-title>Gardasil Vaccine Safety</article-title><year>2009</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/nchs/products/databriefs/db354.htm" ext-link-type="uri">https://www.cdc.gov/nchs/products/databriefs/db354.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-08-22">(accessed on 22 August 2022)</date-in-citation></element-citation></ref><ref id="B7-vaccines-12-01405"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Office of Disease Prevention and Health Promotion</collab>
</person-group><source>Healthy People 2030 Data and Objectives: Increase the Proportion of Adolescents Who Get Recommended Doses of the HPV Vaccine&#x02014;IID-08</source><publisher-name>Office of Disease Prevention and Health Promotion</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2023</year><volume>Volume 2024</volume></element-citation></ref><ref id="B8-vaccines-12-01405"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Office of Disease Prevention and Health Promotion</collab>
</person-group><source>Immunization and Infection Diseases</source><publisher-name>Office of Disease Prevention and Health Promotion</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2020</year><comment>Available online: <ext-link xlink:href="https://wayback.archive-it.org/5774/20220414033335/https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives" ext-link-type="uri">https://wayback.archive-it.org/5774/20220414033335/https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-05-20">(accessed on 20 May 2019)</date-in-citation></element-citation></ref><ref id="B9-vaccines-12-01405"><label>9.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention</collab>
</person-group><article-title>United States Cancer Statistics: Data Visualizations</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fdataviz%2Findex.htm#/RiskFactors/" ext-link-type="uri">https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fdataviz%2Findex.htm#/RiskFactors/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-27">(accessed on 27 April 2024)</date-in-citation></element-citation></ref><ref id="B10-vaccines-12-01405"><label>10.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Tennessee Department of Health</collab>
</person-group><article-title>Immunization Coverage Rate Dashboards</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://www.tn.gov/health/cedep/immunization-program/ip/immunization-fact-sheet/coverage-rate-dashboard.html" ext-link-type="uri">https://www.tn.gov/health/cedep/immunization-program/ip/immunization-fact-sheet/coverage-rate-dashboard.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-27">(accessed on 27 April 2024)</date-in-citation></element-citation></ref><ref id="B11-vaccines-12-01405"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meites</surname><given-names>E.</given-names></name>
<name><surname>Szilagyi</surname><given-names>P.G.</given-names></name>
<name><surname>Chesson</surname><given-names>H.W.</given-names></name>
<name><surname>Unger</surname><given-names>E.R.</given-names></name>
<name><surname>Romero</surname><given-names>J.R.</given-names></name>
<name><surname>Markowitz</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2019</year><volume>68</volume><fpage>698</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6832a3</pub-id></element-citation></ref><ref id="B12-vaccines-12-01405"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adjei Boakye</surname><given-names>E.</given-names></name>
<name><surname>Lew</surname><given-names>D.</given-names></name>
<name><surname>Muthukrishnan</surname><given-names>M.</given-names></name>
<name><surname>Tobo</surname><given-names>B.B.</given-names></name>
<name><surname>Rohde</surname><given-names>R.L.</given-names></name>
<name><surname>Varvares</surname><given-names>M.A.</given-names></name>
<name><surname>Osazuwa-Peters</surname><given-names>N.</given-names></name>
</person-group><article-title>Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18&#x02013;26 year olds in the United States</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>2016</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1467203</pub-id><pub-id pub-id-type="pmid">29708826</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01405"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>P.-j.</given-names></name>
<name><surname>Rodriguez-Lainz</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Halloran</surname><given-names>A.</given-names></name>
<name><surname>Greby</surname><given-names>S.</given-names></name>
<name><surname>Williams</surname><given-names>W.W.</given-names></name>
</person-group><article-title>Adult vaccination disparities among foreign-born populations in the US, 2012</article-title><source>Am. J. Prev. Med.</source><year>2014</year><volume>47</volume><fpage>722</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2014.08.009</pub-id><pub-id pub-id-type="pmid">25300733</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01405"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>A.R.</given-names></name>
<name><surname>Hashibe</surname><given-names>M.</given-names></name>
<name><surname>Bodson</surname><given-names>J.</given-names></name>
<name><surname>Gren</surname><given-names>L.H.</given-names></name>
<name><surname>Taylor</surname><given-names>B.A.</given-names></name>
<name><surname>Greenwood</surname><given-names>J.</given-names></name>
<name><surname>Jackson</surname><given-names>B.R.</given-names></name>
<name><surname>She</surname><given-names>R.</given-names></name>
<name><surname>Egger</surname><given-names>M.J.</given-names></name>
<name><surname>Kepka</surname><given-names>D.</given-names></name>
</person-group><article-title>Factors related to HPV vaccine uptake and 3-dose completion among women in a low vaccination region of the USA: An observational study</article-title><source>BMC Womens Health</source><year>2016</year><volume>16</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1186/s12905-016-0323-5</pub-id><pub-id pub-id-type="pmid">27449775</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01405"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goel</surname><given-names>K.</given-names></name>
<name><surname>Vasudevan</surname><given-names>L.</given-names></name>
</person-group><article-title>Disparities in healthcare access and utilization and human papillomavirus (HPV) vaccine initiation in the United States</article-title><source>Hum. Vaccin. Immunother.</source><year>2021</year><volume>17</volume><fpage>5390</fpage><lpage>5396</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1989919</pub-id><pub-id pub-id-type="pmid">34736353</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01405"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cernasev</surname><given-names>A.</given-names></name>
<name><surname>Hohmeier</surname><given-names>K.C.</given-names></name>
<name><surname>Oyedeji</surname><given-names>O.</given-names></name>
<name><surname>Kintziger</surname><given-names>K.W.</given-names></name>
<name><surname>Hagemann</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Views of the Pharmacists&#x02019; Role in HPV Vaccinations: A Qualitative Study in Tennessee</article-title><source>Pharmacy</source><year>2024</year><volume>12</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.3390/pharmacy12020057</pub-id><pub-id pub-id-type="pmid">38668083</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01405"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cernasev</surname><given-names>A.</given-names></name>
<name><surname>Hohmeier</surname><given-names>K.C.</given-names></name>
<name><surname>Oyedeji</surname><given-names>O.</given-names></name>
<name><surname>Hagemann</surname><given-names>T.</given-names></name>
<name><surname>Kintziger</surname><given-names>K.W.</given-names></name>
<name><surname>Wisdom</surname><given-names>T.</given-names></name>
<name><surname>Gatwood</surname><given-names>J.</given-names></name>
</person-group><article-title>Perspectives associated with human papillomavirus vaccination in adults: A qualitative study</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>850</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11040850</pub-id><pub-id pub-id-type="pmid">37112762</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01405"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oyedeji</surname><given-names>O.</given-names></name>
<name><surname>Wisdom</surname><given-names>T.</given-names></name>
<name><surname>Kintziger</surname><given-names>K.</given-names></name>
<name><surname>Cernasev</surname><given-names>A.</given-names></name>
<name><surname>Hohmeier</surname><given-names>K.</given-names></name>
<name><surname>Hagemann</surname><given-names>T.</given-names></name>
<name><surname>Gatwood</surname><given-names>J.</given-names></name>
</person-group><article-title>Health Behavior Frameworks Describing HPV Vaccine Uptake in Adults: A Scoping Review</article-title><source>J. Prev. Health Promot.</source><year>2024</year><volume>5</volume><fpage>568</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1177/26320770241252935</pub-id></element-citation></ref><ref id="B19-vaccines-12-01405"><label>19.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>U.S. Department of Agriculture</collab>
</person-group><article-title>Rural-Urban Commuting Area Codes</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/" ext-link-type="uri">https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-06">(accessed on 6 March 2024)</date-in-citation></element-citation></ref><ref id="B20-vaccines-12-01405"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cernasev</surname><given-names>A.</given-names></name>
<name><surname>Oyedeji</surname><given-names>O.</given-names></name>
<name><surname>Springer</surname><given-names>C.M.</given-names></name>
<name><surname>Hagemann</surname><given-names>T.M.</given-names></name>
<name><surname>Hohmeier</surname><given-names>K.C.</given-names></name>
<name><surname>Kintziger</surname><given-names>K.W.</given-names></name>
</person-group><article-title>Demographic Influences on Adult HPV Vaccination: Results from a Cross-Sectional Survey in Tennessee</article-title><source>Healthcare</source><year>2024</year><volume>12</volume><elocation-id>1305</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare12131305</pub-id><pub-id pub-id-type="pmid">38998840</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01405"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reiter</surname><given-names>P.L.</given-names></name>
<name><surname>Bustamante</surname><given-names>G.</given-names></name>
<name><surname>McRee</surname><given-names>A.-L.</given-names></name>
</person-group><article-title>HPV vaccine coverage and acceptability among a national sample of sexual minority women ages 18&#x02013;45</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>4956</fpage><lpage>4963</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.06.001</pub-id><pub-id pub-id-type="pmid">32536546</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01405"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alber</surname><given-names>J.M.</given-names></name>
<name><surname>Askay</surname><given-names>D.</given-names></name>
<name><surname>Kolodziejski</surname><given-names>L.R.</given-names></name>
<name><surname>Ghazvini</surname><given-names>S.</given-names></name>
<name><surname>Tolentino</surname><given-names>B.</given-names></name>
<name><surname>Gibbs</surname><given-names>S.L.</given-names></name>
</person-group><article-title>HPV vaccine-related beliefs and knowledge among adults 18&#x02013;45 years old</article-title><source>Am. J. Health Ed.</source><year>2021</year><volume>52</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1080/19325037.2020.1844102</pub-id></element-citation></ref><ref id="B23-vaccines-12-01405"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kellogg</surname><given-names>C.</given-names></name>
<name><surname>Shu</surname><given-names>J.</given-names></name>
<name><surname>Arroyo</surname><given-names>A.</given-names></name>
<name><surname>Dinh</surname><given-names>N.T.</given-names></name>
<name><surname>Wade</surname><given-names>N.</given-names></name>
<name><surname>Sanchez</surname><given-names>E.</given-names></name>
<name><surname>Equils</surname><given-names>O.</given-names></name>
</person-group><article-title>A significant portion of college students are not aware of HPV disease and HPV vaccine recommendations</article-title><source>Hum. Vaccin. Immunother.</source><year>2019</year><volume>15</volume><fpage>1760</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1627819</pub-id><pub-id pub-id-type="pmid">31166148</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01405"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guadiana</surname><given-names>D.</given-names></name>
<name><surname>Kavanagh</surname><given-names>N.M.</given-names></name>
<name><surname>Squarize</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Oral health care professionals recommending and administering the HPV vaccine: Understanding the strengths and assessing the barriers</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0248047</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0248047</pub-id><pub-id pub-id-type="pmid">33662007</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01405"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>C.</given-names></name>
<name><surname>Shen</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
</person-group><article-title>Therapeutic DNA vaccines against HPV-related malignancies: Promising leads from clinical trials</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>239</elocation-id><pub-id pub-id-type="doi">10.3390/v14020239</pub-id><pub-id pub-id-type="pmid">35215833</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01405"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>K.</given-names></name>
<name><surname>Gr&#x000f8;nh&#x000f8;j</surname><given-names>C.</given-names></name>
<name><surname>Hahn</surname><given-names>C.H.</given-names></name>
<name><surname>von Buchwald</surname><given-names>C.</given-names></name>
</person-group><article-title>Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>6594</fpage><lpage>6605</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.09.027</pub-id><pub-id pub-id-type="pmid">30268734</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01405"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pham</surname><given-names>C.T.</given-names></name>
<name><surname>Juhasz</surname><given-names>M.</given-names></name>
<name><surname>Sung</surname><given-names>C.T.</given-names></name>
<name><surname>Mesinkovska</surname><given-names>N.A.</given-names></name>
</person-group><article-title>The human papillomavirus vaccine as a treatment for human papillomavirus&#x02013;related dysplastic and neoplastic conditions: A literature review</article-title><source>J. Am. Acad. Dermatol.</source><year>2020</year><volume>82</volume><fpage>202</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2019.04.067</pub-id><pub-id pub-id-type="pmid">31085272</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01405"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walter</surname><given-names>L.A.</given-names></name>
<name><surname>Leader</surname><given-names>E.</given-names></name>
<name><surname>Galbraith</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Human papillomavirus awareness, vaccine status, and risk factors in female emergency patients</article-title><source>West. J. Emerg. Med.</source><year>2020</year><volume>21</volume><fpage>203</fpage><pub-id pub-id-type="doi">10.5811/westjem.2019.12.44422</pub-id><pub-id pub-id-type="pmid">32191177</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01405"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Wen</surname><given-names>K.-Y.</given-names></name>
<name><surname>Juon</surname><given-names>H.-S.</given-names></name>
</person-group><article-title>Disparities in awareness of the HPV vaccine and HPV-associated cancers among racial/ethnic minority populations: 2018 HINTS</article-title><source>Ethn. Health</source><year>2023</year><volume>28</volume><fpage>586</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1080/13557858.2022.2116630</pub-id><pub-id pub-id-type="pmid">36045478</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01405"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ojeaga</surname><given-names>A.</given-names></name>
<name><surname>Alema-Mensah</surname><given-names>E.</given-names></name>
<name><surname>Rivers</surname><given-names>D.</given-names></name>
<name><surname>Azonobi</surname><given-names>I.</given-names></name>
<name><surname>Rivers</surname><given-names>B.</given-names></name>
</person-group><article-title>Racial disparities in HPV-related knowledge, attitudes, and beliefs among African American and white women in the USA</article-title><source>J. Cancer Educ.</source><year>2019</year><volume>34</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s13187-017-1268-6</pub-id><pub-id pub-id-type="pmid">28808906</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01405"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bond</surname><given-names>S.M.</given-names></name>
<name><surname>Cartmell</surname><given-names>K.B.</given-names></name>
<name><surname>Lopez</surname><given-names>C.M.</given-names></name>
<name><surname>Ford</surname><given-names>M.E.</given-names></name>
<name><surname>Brandt</surname><given-names>H.M.</given-names></name>
<name><surname>Gore</surname><given-names>E.I.</given-names></name>
<name><surname>Zapka</surname><given-names>J.G.</given-names></name>
<name><surname>Alberg</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Racial and ethnic group knowledge, perceptions and behaviors about human papillomavirus, human papillomavirus vaccination, and cervical cancer among adolescent females</article-title><source>J. Pediatr. Adolesc. Gynecol.</source><year>2016</year><volume>29</volume><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.jpag.2016.02.005</pub-id><pub-id pub-id-type="pmid">26915922</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01405"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>N.L.</given-names></name>
<name><surname>Biddell</surname><given-names>C.B.</given-names></name>
<name><surname>Rhodes</surname><given-names>B.E.</given-names></name>
<name><surname>Brewer</surname><given-names>N.T.</given-names></name>
</person-group><article-title>Provider communication and HPV vaccine uptake: A meta-analysis and systematic review</article-title><source>Prev. Med.</source><year>2021</year><volume>148</volume><fpage>106554</fpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106554</pub-id><pub-id pub-id-type="pmid">33857561</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01405"><label>33.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Tennessee Department of Health</collab>
</person-group><article-title>Epidemiology and Surveillance Data</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://data.tn.gov/t/Public/views/Adult_Dash_Q2_for_publication/Adult_Dash?%3Aembed=yes&#x00026;%3Atoolbar=no&#x00026;%3Atabs=no" ext-link-type="uri">https://data.tn.gov/t/Public/views/Adult_Dash_Q2_for_publication/Adult_Dash?%3Aembed=yes&#x00026;%3Atoolbar=no&#x00026;%3Atabs=no</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="vaccines-12-01405-t001"><object-id pub-id-type="pii">vaccines-12-01405-t001_Table 1</object-id><label>Table 1</label><caption><p>Factor loadings by survey item.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Survey Item <sup>1</sup></th><th colspan="5" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Factor Loading <sup>2</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Benefits 3. Getting vaccinated for HPV will decrease my chances of developing genital warts.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.816</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Benefits 4. Getting vaccinated for HPV will decrease my chances of developing oral cancer.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.783</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Benefits 2. If I get vaccinated for HPV, I can reduce my risk of cervical/penile or anal cancer.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.776</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Benefits 1. Getting vaccinated for HPV will help protect me from genital HPV infection.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.746</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Trust 1. I trust my healthcare provider&#x02019;s decisions about which medical treatments are best for me.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.728</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Trust 2. My healthcare provider is honest in telling me about all of the different treatment options available for my condition.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.647</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">Trust 4. All in all, I have complete trust in my healthcare provider.</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9E2F3" rowspan="1" colspan="1">0.629</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">Susceptibility 4. If I do not get vaccinated for HPV, it is likely that I will develop a HPV-related cancer (e.g., oral, cervical, or penile) in the future.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">0.863</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">Susceptibility 2. If I do not get vaccinated for HPV and continue my current behaviors, it is likely I will become infected with genital HPV or develop genital warts in the future.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">0.862</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">Susceptibility 3. If I do not get vaccinated for HPV, I would feel vulnerable to developing a future genital HPV infection or genital warts sometime in the future.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">0.839</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">Susceptibility 5. If I do not get vaccinated for HPV, I would feel vulnerable to developing HPV-related cancer (e.g., oral, cervical, or penile) sometime in the future.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">0.807</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">Susceptibility 1. My current behaviors (e.g., sexual activity, drug use) put me at risk for HPV.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">0.767</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">Behavior Control 2. I am confident I can get all the recommended doses of the HPV vaccine in the next 12 months, even if my schedule is busy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">0.806</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">Behavior Control 1. I am confident I can get all the recommended doses of the HPV vaccine in the next 12 months, even if there is a financial burden.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">0.802</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">Behavior Control 3. I am confident I can find a healthcare provider (for example, clinic, health center, physician&#x02019;s office) where I can get all the recommended doses of the HPV vaccine in the next 12 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">0.677</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">Attitude 2. I think getting all the recommended doses of the HPV vaccine in the next 12 months is necessary.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">0.651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">Attitude 3. I think getting all the recommended doses of the HPV vaccine in the next 12 months would be beneficial.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">0.636</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">Attitude 1. I think getting all the recommended doses of the HPV vaccine in the next 12 months would be protective.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFF2CC" rowspan="1" colspan="1">0.600</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Barriers 2. Concerns about whether the vaccine is safe.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">0.824</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Barriers 1. Concerns about possible side effects of the vaccine.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">0.805</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Barriers 4. I do not have enough information about the HPV vaccine.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">0.762</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Barriers 3. I do not have enough information about HPV.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">0.755</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E0E0E0" rowspan="1" colspan="1">Severity 3. Having genital warts would have major consequences on my life.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.822</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E0E0E0" rowspan="1" colspan="1">Severity 1. Having cervical/penile or anal cancer due to HPV would have major consequences on my life.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.821</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#E0E0E0" rowspan="1" colspan="1">Severity 2. Having cervical/penile or anal cancer due to HPV would be devastating for me.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.818</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Colors are used to highlight the distinct factors identified. <sup>2</sup> Extraction method: Principal Components Analysis. Rotation method: Varimax with Kaiser Normalization. Factor 1: Benefits/Trust, Factor 2: Perceived Susceptibility, Factor 3: Attitudes/Behavioral Control, Factor 4: Perceived Barriers, Factor 5: Perceived Severity.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01405-t002"><object-id pub-id-type="pii">vaccines-12-01405-t002_Table 2</object-id><label>Table 2</label><caption><p>Factor summary statistics and internal reliability.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% Variance <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>3</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cronbach&#x02019;s Alpha</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1. Benefits/Trust</td><td align="center" valign="middle" rowspan="1" colspan="1">19.675</td><td align="center" valign="middle" rowspan="1" colspan="1">5.04</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.908</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2. Perceived Susceptibility</td><td align="center" valign="middle" rowspan="1" colspan="1">15.306</td><td align="center" valign="middle" rowspan="1" colspan="1">3.46</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.901</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3. Attitude/Behavioral Control</td><td align="center" valign="middle" rowspan="1" colspan="1">14.761</td><td align="center" valign="middle" rowspan="1" colspan="1">4.77</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.908</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4. Perceived Barriers</td><td align="center" valign="middle" rowspan="1" colspan="1">10.460</td><td align="center" valign="middle" rowspan="1" colspan="1">4.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.874</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5. Perceived Severity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.809</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Percent of total variance explained by each factor. <sup>2</sup> Average of items within each factor. <sup>3</sup> Standard deviation of items within each factor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01405-t003"><object-id pub-id-type="pii">vaccines-12-01405-t003_Table 3</object-id><label>Table 3</label><caption><p>Correlations matrix of factors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor 1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor 2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor 3</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor 4</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor 5</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1: Benefits/Trust</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.285 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.655 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">0.569 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2: Perceived Susceptibility</td><td align="center" valign="middle" rowspan="1" colspan="1">0.285 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.381 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.140 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3: Attitudes/Behavioral Control</td><td align="center" valign="middle" rowspan="1" colspan="1">0.655 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.381 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.157 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.491 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4: Perceived Barriers</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.157 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.089 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5: Perceived Severity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.569 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.140 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.491 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.089 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01405-t004"><object-id pub-id-type="pii">vaccines-12-01405-t004_Table 4</object-id><label>Table 4</label><caption><p>Means of factors by vaccination status.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Factor</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Vaccination Status</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Unvaccinated (<italic toggle="yes">n</italic> = 1148)</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccinated (<italic toggle="yes">n</italic> = 855)</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>2</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Benefits/Trust</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2: Perceived Susceptibility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3: Attitudes/Behavioral Control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4: Perceived Barriers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5: Perceived Severity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Average of items within each factor. <sup>2</sup> Standard deviation of items within each factor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01405-t005"><object-id pub-id-type="pii">vaccines-12-01405-t005_Table 5</object-id><label>Table 5</label><caption><p>Means of factors by age.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccination Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1: Benefits/Trust <sup>3</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;28 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9517</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35621</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">996</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;38 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9961</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35540</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">504</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39&#x02013;45 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9503</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.36615</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">503</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2. Perceived Susceptibility</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Unvaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;28 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1079</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.49845</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">492</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;38 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.1271</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.59065</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39&#x02013;45 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.9148</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.62159</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">379</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;28 years old <sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8989</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.62254</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">504</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;38 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.1075</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.59803</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">227</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39&#x02013;45 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3855</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.77611</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3: Attitudes/Behavioral Control <sup>4</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;28 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.7641</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.51152</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">996</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;38 years old <sup>5,6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9194</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.44115</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">504</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39&#x02013;45 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6591</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.48350</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">503</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4: Perceived Barriers <sup>3</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;28 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9517</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35621</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">996</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;38 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9961</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35540</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">504</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39&#x02013;45 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.9503</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.36615</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">503</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5: Perceived Severity <sup>4</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;28 years old <sup>5,7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.2711</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.65268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">996</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29&#x02013;38 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.4964</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.60073</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">504</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39&#x02013;45 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5891</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.62592</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">503</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Average of items within each factor. <sup>2</sup> Standard deviation of items within each factor. <sup>3</sup> No significant effects found for main effect or interaction of main effect by vaccination status. <sup>4</sup> No significant interaction found for main effect by vaccination status, so only descriptive statistics by main effect reported. <sup>5</sup> Significant effects identified compared to 39&#x02013;45-year-old participants (<italic toggle="yes">p</italic>-values &#x0003c; 0.05). <sup>6</sup> Significant effects identified compared to 18&#x02013;28-year-old participants (<italic toggle="yes">p</italic>-values &#x0003c; 0.05). <sup>7</sup> Significant effects identified compared to 39&#x02013;45-year-old participants (<italic toggle="yes">p</italic>-values &#x0003c; 0.05). </p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01405-t006"><object-id pub-id-type="pii">vaccines-12-01405-t006_Table 6</object-id><label>Table 6</label><caption><p>Means of factors by sex at birth.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Factor</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sex</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Male (<italic toggle="yes">n</italic> = 961)</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Female (<italic toggle="yes">n</italic> = 1050)</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>2</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>1</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>2</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1: Benefits/Trust</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.963</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.973</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.049</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.839</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.153</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2: Perceived Susceptibility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.622</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.422</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.463</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.197</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.029</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3: Attitudes/Behavioral Control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.820</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.063</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.902</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.883</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.184</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4: Perceived Barriers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.306</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.242</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.236</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.063</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.300</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5: Perceived Severity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.291</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.242</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.554</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.242</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Average of items within each factor. <sup>2</sup> Standard deviation of items within each factor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01405-t007"><object-id pub-id-type="pii">vaccines-12-01405-t007_Table 7</object-id><label>Table 7</label><caption><p>Means of factors by race.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccination<break/>Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Race</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SD <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1: Benefits/Trust <sup>4</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0118</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35846</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1550</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black <sup>5,6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.7487</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32908</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">356</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.2143</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.28407</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2. Perceived Susceptibility</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Unvaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White <sup>6,7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.9334</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.58214</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">894</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4201</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.33048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">206</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.7917</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.84672</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.70414</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">656</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9133</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41088</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.4333</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31283</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3: Attitudes/Behavioral Control</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Unvaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2463</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.38480</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">894</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.1362</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.26799</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">206</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian <sup>5,7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.1389</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.30001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5727</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.28349</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">656</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black <sup>5,6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.1171</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.47651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8241</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.19157</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4: Perceived Barriers <sup>3</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3219</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.52378</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1550</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2835</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.42419</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">356</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.34005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5: Perceived Severity <sup>3</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5296</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.59973</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1550</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Black <sup>5,6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8876</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.70460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">356</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.4286</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.52181</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Average of items within each factor. <sup>2</sup> Standard deviation of items within each factor. <sup>3</sup> No significant effects found for main effect or interaction of main effect by vaccination status, so only descriptive statistics by main effect reported. <sup>4</sup> No significant interaction found for main effect by vaccination status, so only descriptive statistics by main effect reported. <sup>5</sup> Significant effects identified compared to White participants (<italic toggle="yes">p</italic>-values &#x0003c; 0.05). <sup>6</sup> Significant effects identified compared to Asian participants (<italic toggle="yes">p</italic>-values &#x0003c; 0.05). <sup>7</sup> Significant effects identified compared to Black participants (<italic toggle="yes">p</italic>-values &#x0003c; 0.05).</p></fn></table-wrap-foot></table-wrap></floats-group></article>